{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-25-274314","form_type":"8-K","ticker":"PROK","cik":"0001850270","company_name":"PROKIDNEY CORP.","filed_at":"2025-11-10T23:59:59+00:00","discovered_at":"2026-05-14T18:02:40.809251+00:00","generated_at":"2026-05-16T22:36:58.599910+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"ProKidney reports Q3 net loss $35.8M, cash $271.7M; Phase 3 PROACT 1 enrollment >50%, topline Q2 2027","bullets":["Q3 net loss before noncontrolling interest $35.8M vs $41.1M YoY; R&D expenses $26.8M.","Cash and equivalents $271.7M, expected to fund operations into mid-2027.","Phase 3 PROACT 1 accelerated approval analysis: >50% of ~360 patients enrolled, topline results Q2 2027.","FDA confirmed eGFR slope as surrogate endpoint for BLA under accelerated approval; RMAT designation continues.","Phase 2 REGEN-007 data at ASN: 78% improvement in eGFR decline (p<0.001); well tolerated."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-25-274314","json":"https://secwatch.observer/filing/0001193125-25-274314.json","markdown":"https://secwatch.observer/filing/0001193125-25-274314.md","text":"https://secwatch.observer/filing/0001193125-25-274314.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1850270/000119312525274314/0001193125-25-274314-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1850270/000119312525274314/prok-20251110.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-16T22:36:58.599910+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}